Healthcare provider profile · identity verified

Michael Lawrence Glavin, MD

Psychiatry · OTTAWA, IL · NPI 1376629741

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Quetiapine Fumarate	Quetiapine Fumarate	644	83
Lorazepam	Lorazepam	636	81
Clonazepam	Clonazepam	569	59
Alprazolam	Alprazolam	560	66
Duloxetine Hcl	Duloxetine Hcl	464	67
Venlafaxine Hcl Er	Venlafaxine Hcl	378	51
Fluoxetine Hcl	Fluoxetine Hcl	348	54
Aripiprazole	Aripiprazole	347	64
Trazodone Hcl	Trazodone Hcl	339	61
Lamotrigine	Lamotrigine	337	61
Hydroxyzine Hcl	Hydroxyzine Hcl	305	63
Olanzapine	Olanzapine	302	42
Risperidone	Risperidone	276	39
Mirtazapine	Mirtazapine	270	50
Sertraline Hcl	Sertraline Hcl	244	41
Benztropine Mesylate	Benztropine Mesylate	235	42
Divalproex Sodium Er	Divalproex Sodium	235	31
Buspirone Hcl	Buspirone Hcl	206	37
Escitalopram Oxalate	Escitalopram Oxalate	178	36
Gabapentin	Gabapentin	159	26
Lurasidone Hcl	Lurasidone Hcl	153	19
Diazepam	Diazepam	152	22
Zolpidem Tartrate	Zolpidem Tartrate	145	25
Citalopram Hbr	Citalopram Hydrobromide	134	22
Divalproex Sodium	Divalproex Sodium	131	26
Bupropion Hcl Sr	Bupropion Hcl	129	26
Paroxetine Hcl	Paroxetine Hcl	126	19
Ziprasidone Hcl	Ziprasidone Hcl	125	16
Donepezil Hcl	Donepezil Hcl	120	27
Topiramate	Topiramate	116	21
Haloperidol	Haloperidol	112	14
Propranolol Hcl	Propranolol Hcl	99	15
Vraylar	Cariprazine Hcl	90	13
Fluphenazine Hcl	Fluphenazine Hcl	89	11
Memantine Hcl	Memantine Hcl	82	14
Metformin Hcl	Metformin Hcl	80	12
Clozapine	Clozapine	78	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	73	11
Zaleplon	Zaleplon	68	suppressed
Prazosin Hcl	Prazosin Hcl	65	11
Ingrezza	Valbenazine Tosylate	64	suppressed
Bupropion Xl	Bupropion Hcl	63	suppressed
Clomipramine Hcl	Clomipramine Hcl	61	suppressed
Lithium Carbonate	Lithium Carbonate	61	13
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	53	12
Venlafaxine Hcl	Venlafaxine Hcl	52	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	50	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	47	suppressed
Naltrexone Hcl	Naltrexone Hcl	45	suppressed
Amlodipine Besylate	Amlodipine Besylate	42	suppressed
Lithium Carbonate Er	Lithium Carbonate	34	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	34	suppressed
Temazepam	Temazepam	33	suppressed
Eszopiclone	Eszopiclone	31	suppressed
Ondansetron Hcl	Ondansetron Hcl	28	suppressed
Bupropion Hcl	Bupropion Hcl	26	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	25	suppressed
Doxepin Hcl	Doxepin Hcl	23	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	23	suppressed
Modafinil	Modafinil	22	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	21	suppressed
Metoprolol Succinate	Metoprolol Succinate	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Carbamazepine	Carbamazepine	20	suppressed
Oxcarbazepine	Oxcarbazepine	20	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	18	suppressed
Carbamazepine Er	Carbamazepine	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Vilazodone Hcl	Vilazodone Hcl	18	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	17	suppressed
Ramelteon	Ramelteon	17	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	17	suppressed
Caplyta	Lumateperone Tosylate	14	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	14	suppressed
Rexulti	Brexpiprazole	14	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	13	suppressed
Paliperidone Er	Paliperidone	13	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Estazolam	Estazolam	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Trintellix	Vortioxetine Hydrobromide	12	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error